Richard E. Harris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richard E. Harris has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Adrianna Vlachos
Schneiders Children’s Hospital, Long Island Jewish, Long Island, NY
1 shared publicationAlexandra Filipovich
Divisions of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH
1 shared publicationAmanda M. Termuhlen
Division of Hematology/Oncology, Nationwide Children’s Hospital, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH
1 shared publication- Arleen D. Auerbach
The Rockefeller University
1 shared publication Azadeh Farzin
Divisions of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
1 shared publicationFranklin O. Smith
Divisions of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH
1 shared publication
Latest Publications
- Open Access
- 1 February 2011
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 17 (2) , 249-258
Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children’s Oncology Group Study A5962
- 1 February 2011
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 17 (2) , 249-258
Open AccessAutologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children’s Oncology Group Study A5962
- Open Access
- 8 January 2007
- Published by Wiley in British Journal of Haematology
- Vol. 136 (4) , 633-640
Matched sibling donor haematopoietic stem cell transplantation in Fanconi anaemia: an update of the Cincinnati Children's experience
Our results for 18 patients undergoing matched sibling donor stem cell transplant for Fanconi anaemia at Cincinnati Children's Hospital Medical Center were published in 1994. The present report updates our results in 35 consecutive patients. Thirty patients transplanted for marrow aplasia received cyclophosphamide 5 mg/kg for 4 d and 400 cGy thoraco‐abdominal irradiation. Five patients with clones involving chromosome 7, myelodysplastic syndrome or leukaemia received a more aggressive regimen with total body irradiation. Horse antithymocyte globulin was administered in the pretransplant period to promote engraftment and in the post‐transplant period for additional graft‐versus‐host disease (GVHD) prophylaxis. The median age at bone marrow transplantation was 7·6 years. Median day of engraftment was day +12 (range 9–49), eight patients developed acute GVHD and four chronic GVHD, one limited and three extensive. Twenty‐nine of 35 patients (89% actuarial survival at 10 years) had survived with a median follow up of 10·2 years; two children had developed secondary malignancy. All surviving patients had normal blood counts with full donor engraftment. These data indicate excellent long‐term outcomes and serve as a reference for newer radiation‐free preparative regimes that may reduce the risk of late secondary malignancy.
- 8 January 2007
- Published by Wiley in British Journal of Haematology
- Vol. 136 (4) , 633-640
Open AccessMatched sibling donor haematopoietic stem cell transplantation in Fanconi anaemia: an update of the Cincinnati Children's experience
Our results for 18 patients undergoing matched sibling donor stem cell transplant for Fanconi anaemia at Cincinnati Children's Hospital Medical Center were published in 1994. The present report updates our results in 35 consecutive patients. Thirty patients transplanted for marrow aplasia received cyclophosphamide 5 mg/kg for 4 d and 400 cGy thoraco‐abdominal irradiation. Five patients with clones involving chromosome 7, myelodysplastic syndrome or leukaemia received a more aggressive regimen with total body irradiation. Horse antithymocyte globulin was administered in the pretransplant period to promote engraftment and in the post‐transplant period for additional graft‐versus‐host disease (GVHD) prophylaxis. The median age at bone marrow transplantation was 7·6 years. Median day of engraftment was day +12 (range 9–49), eight patients developed acute GVHD and four chronic GVHD, one limited and three extensive. Twenty‐nine of 35 patients (89% actuarial survival at 10 years) had survived with a median follow up of 10·2 years; two children had developed secondary malignancy. All surviving patients had normal blood counts with full donor engraftment. These data indicate excellent long‐term outcomes and serve as a reference for newer radiation‐free preparative regimes that may reduce the risk of late secondary malignancy.